Secondary Logo

​​​​​​​​​​HemOncTimes      

     Leukemia​          Lymphoma         Multiple Myeloma​

Online Exclusive

CML.jpeg

Ibrutinib More Effective Compared to Standard CLL Treatment

A  new study has found that a newer targeted drug is significantly more effective than standard therapy for treating elderly patients with chronic lymphocytic leukemia.


FDA Alert

CML.jpeg

Daratumumab Split-Dosing Regimen Approved for Multiple Myeloma

This daratumumab regimen provides health care professionals and patients with multiple myeloma an option to split the first infusion over 2 consecutive days. 


Your Career Path

CML.jpeg

Transitioning Into a Leadership Role & Finding Success

What does it mean to be a leader? While there can be a number of different answers, a fundamental part of leadership is recognizing that it isn't about you.

 


ASH 2018 Coverage

CML.jpegMicrobiome Diversity Key to Survival After Allo-HCT

By Peter M. Goodwin

Overall survival after allo-HCT was found to be adversely influenced by a lack of diversity in the intestinal microbiota.


CML.jpeg

Personalized Prediction Model Improves Prognosis in Myelodysplastic Syndromes

By Mark L. Fuerst

A personalized, machine learning-based prediction model can help clinicians risk stratify patients with myelodysplastic syndromes.


CML.jpeg

Initial Data on Lisocabtagene Maraleucel in R/R Chronic Lymphocytic Leukemia

By Richard Simoneaux

Although the treatment of CLL has drastically changed over the past few years complete response rates remain low, thus necessitating the use of continuous therapy. 



From the Issue

Video.png 

Cardio-Oncology: Matters of the Heart in Hematologic Cancers

Cardio-oncology is a collaborative effort between cardiology and oncology to address relationships between cancer, cancer treatments, and heart health.

Immune Checkpoint Combinations in Classical Hodgkin Lymphoma

The use of antibodies that block PD-1/PD-1 ligand signaling have resulted in high response rates in clinical trials and have led to the approval of nivolumab and pembrolizumab in patients with relapsed and refractory classical Hodgkin lymphoma.

Editorial

Rare Blood Cancers in 2018 & Beyond

A surprisingly With the increased understanding of underlying disease state mechanisms and our immune system, new targeted chemo and immunotherapy approaches have been developed for the treatment of many forms of cancer.

More on Genomics

Genomics Within the Clinical Workflow: A New Standard of Care

Few advances in recent decades have the potential to change health care practice as significantly as genomics and precision medicine. Not surprisingly, oncology is proving to be the standard bearer in the charge.

Research Minute

Read More Research Highlights

Are you looking for the latest hematology/oncology research? Check out additional highlights featuring the cutting-edge discoveries in the field.

Free Downloads

Patient Handouts

Looking for resources to share with your colleagues and patients? Check out patient handouts on a variety of topics, including “Maximizing Resilience,” which encourages patients to think about resilience in new ways and take steps to building this quality.